Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 224 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Whole Body PET/CT Scan Clear all
Not listed Phase 1 Interventional

Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer

NCT04052412
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
18F-AraG
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 24, 2026, 5:07 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Exploratory Evaluation of [11C]-NOP46

NCT03705819
View directory record Official record
Conditions
Chronic Pain
Interventions
[11C]-NOP46, PET/CT scan
Drug · Radiation
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 24, 2026, 5:07 AM EDT
Active, not recruiting Phase 2 Interventional

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

NCT03181867
View directory record Official record
Conditions
Prostate Neoplasms, Prostatic Cancer, Prostate Cancer, Cancer Of Prostate, Metastatic Prostate Cancer
Interventions
18F-DCFPyL, 18F-FDG, PSMA-11
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 5:07 AM EDT
Recruiting Phase 3 Interventional

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

NCT04423211
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy
Radiation · Drug · Procedure + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
341
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 24, 2026, 5:07 AM EDT
Completed Phase 1 Interventional

Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using Fluoro Furanyl Norprogesterone (FFNP)

NCT00968409
View directory record Official record
Conditions
Breast Cancer
Interventions
PET, Laboratory Testing, Safety Testing, F18-FFNP
Radiation · Other · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 24, 2026, 5:07 AM EDT
Not yet recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

NCT07593079
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions
Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3, PROSTest
Drug · Device · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer

NCT02260817
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
11C-choline Injection
Drug
Lead sponsor
Global Isotopes, LLC d/b/a Zevacor Molecular
Industry
Eligibility
18 Years and older · Male only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Decatur, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 24, 2026, 5:07 AM EDT
Recruiting Phase 2 Interventional

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

NCT07393867
View directory record Official record
Conditions
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
Interventions
PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
Diagnostic Test · Drug · Radiation
Lead sponsor
Martin T. King, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 24, 2026, 5:07 AM EDT
Not yet recruiting Phase 2 Interventional

Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET

NCT07285993
View directory record Official record
Conditions
Breast Cancer, Metastatic Invasive Lobular Breast Cancer
Interventions
18F-FAPI-74, 18F-FDG, PET/CT
Drug · Procedure
Lead sponsor
Randy Yeh
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 24, 2026, 5:07 AM EDT
Recruiting Phase 2 Interventional

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

NCT06378866
View directory record Official record
Conditions
Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer, Biochemically Recurrent Prostate Carcinoma
Interventions
Abiraterone, Apalutamide, Biospecimen Collection, Bone Scan, Computed Tomography, Darolutamide, Degarelix, Enzalutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Prednisone, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Radiation Therapy, Image-Guided Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 24, 2026, 5:07 AM EDT
Recruiting Phase 2 Interventional

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

NCT05616650
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
Interventions
18F-DCFPyL, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 5:07 AM EDT
Terminated Phase 2 Interventional

Novel Gallium 68 Citrate in Orthopedic Infections

NCT03123289
View directory record Official record
Conditions
Joint Prosthesis
Interventions
68-Gallium citrate PET/CT scan, 18F FDG PET/CT scan
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 24, 2026, 5:07 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Neuroinflammation FNOS PET/CT in HIV (+) and (-) Subjects With OUD and Healthy Controls

NCT04401917
View directory record Official record
Conditions
HIV Infections, Opioid Use
Interventions
[18F]NOS
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 24, 2026, 5:07 AM EDT
Withdrawn Not applicable Interventional

Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy

NCT02139150
View directory record Official record
Conditions
Histologically-confirmed Malignancies
Interventions
[18F] FLT, PET/CT scans
Radiation · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 24, 2026, 5:07 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Tau PET Imaging in Opioid Use Disorder

NCT05651516
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
18F-PI-2620 PET/CT
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 24, 2026, 5:07 AM EDT
Withdrawn Phase 1 Interventional

Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer

NCT03029871
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage I
Interventions
Ad5-yCD/mutTKSR39rep-ADP Adenovirus
Biological
Lead sponsor
Benjamin Movsas, M.D.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 24, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Studies of Elevated Parathyroid Activity

NCT00001277
View directory record Official record
Conditions
Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm, Multiple Endocrine Neoplasia, MEN1
Interventions
68Ga-Dotatate, 18F-DOPA
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Months and older
Enrollment
1,553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 24, 2026, 5:07 AM EDT
Terminated No phase listed Observational

Maladaptive Adipose Tissue Activity in Cancer

NCT03621124
View directory record Official record
Conditions
Cancer Nos
Interventions
Resting Energy Expenditure, Thermal Comfort Questionnaire
Procedure · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
40 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 24, 2026, 5:07 AM EDT
Terminated Not applicable Interventional

Augmented Whole-body Scanning Via Magnifying PET/CT (AWSM-PET/CT) Techniques Abilities to Improve Upon the Diagnostic Accuracy of the Standard-of-care (SOC) PET/CT for Malignant Lesion Detection

NCT05513027
View directory record Official record
Conditions
Cancer
Interventions
Augmented Whole-body Scanning via Magnifying PET, PET/CT
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 24, 2026, 5:07 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation

NCT04535193
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
18F-mFBG for intravenous administration
Drug
Lead sponsor
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 24, 2026, 5:07 AM EDT
Recruiting Phase 1 Interventional

DK222 Study at Hopkins

NCT07140315
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Urothelial Cancer
Interventions
[18F]DK222 radiotracer
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 24, 2026, 5:07 AM EDT
Completed Phase 2 Interventional

Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease

NCT00315250
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonian Syndrome
Interventions
[123I]β-CIT
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
22 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 24, 2026, 5:07 AM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

Biodistribution & Pharmacokinetic of Position Emission Tomography (PET) Radiopharmaceutical 18F C SNAT4

NCT04017819
View directory record Official record
Conditions
Cancer, Lung Cancer
Interventions
18F-C-SNAT4, Positron emission tomography (PET)/Computed tomography (CT) Scan
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 24, 2026, 5:07 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

64Cu-LLP2A for Imaging Multiple Myeloma

NCT03804424
View directory record Official record
Conditions
Multiple Myeloma
Interventions
64Cu-LLP2A, PET/MR, Blood samples for serum stability, Blood samples for metabolite analysis, Urine sample, Tumor biopsy, Electrocardiogram, PET/CT
Drug · Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 24, 2026, 5:07 AM EDT